• Olivier Ormezzano, Jean-Philippe Baguet, Frédéric Thony, Dominique Blin, Olivier Chavanon, Bertrand Toussaint, Candice Trocmé, Gérald Vanzetto, and Patrice Faure.
• Int. J. Cardiol. 2010 Nov 19; 145 (2): 379-80.

UnlabelledPlasma levels of PIIINP a marker of extracellular matrix metabolism activity have been linked to abdominal aortic aneurysm growth rate, but its relationship with thoracic aortic aneurysm (TAA) growth has never previously been studied.ObjectiveTo demonstrate the value of assay of "aminoterminal propeptide of type III procollagen" (PIIINP) to predict the growth of ascending TAA.Methods And ResultsThirty consecutive patients with asymptomatic ascending TAA were recruited and PIIINP was measured. The patients were then followed up in the usual way, by annual imaging tests. The patients were then divided into two groups: Group 1=patients with a stable TAA or with a slow growth rate (≤2 mm/year) (n=23) and Group 2=patients with a fast-growing TAA (>2 mm/year) (n=7). Mean age of the patients was 65.8±10.8 years. At inclusion, the mean value for maximum aneurysm diameter was 44.6±3.4 mm. The mean follow-up period was 1.6±0.8 years. The patients presenting a significant increase in maximum aneurysm size have a significantly higher PIIINP level than those demonstrating no or limited growth in maximum aneurysm diameter (4.51±1.09 vs 3.38±0.96 µg/l respectively, p=0.02). There is no difference between the two groups for the other clinical or laboratory parameters. Following multivariate analysis the PIIINP level remains significantly higher in Group 1 (p=0.03).ConclusionsOur results suggest that it may in the future be possible to monitor TAA growth by means of PIIINP levels.Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

17 keywords...

hide…